Online Program Home
My Program

Abstract Details

Activity Number: 658
Type: Contributed
Date/Time: Thursday, August 4, 2016 : 8:30 AM to 10:20 AM
Sponsor: Biopharmaceutical Section
Abstract #320007 View Presentation
Title: Deconstructing the Measure of Vaccine Efficacy Against Disease Irrespective of HPV in HPV Vaccine Clinical Trials
Author(s): Oliver Bautista* and Alain Luxembourg
Companies: Merck and Merck
Keywords: Vaccine efficacy ; Disease endpoint irrespective of HPV ; Confounding
Abstract:

Human papillomavirus (HPV) vaccines prevent anogenital disease caused by specific HPV types. The impact of HPV vaccination on the overall burden of disease, irrespective of HPV, is an important public health question. Attempts were made to use clinical trial data to assess such impact. However, the interpretation of vaccine efficacy (VE) on the endpoint of disease irrespective of HPV is not widely understood. We used the GARDASIL 9 clinical program as a case study to assess the value of measuring VE in such endpoint. The assessment used heuristic reasoning and probability calculations. VE in the irrespective of HPV endpoint is driven simultaneously in opposite directions by the high estimate of prophylactic efficacy and a numerically negative estimate of risk reduction that also reflects of high prophylactic efficacy in the absence of cross-protection. The VE estimate in the irrespective of HPV endpoint is ambiguous and difficult to interpret. Comparing this estimate across different HPV vaccine studies requires for each study an understanding of the contributions of vaccine HPV type efficacy and the incidence of disease not related to vaccine HPV types.


Authors who are presenting talks have a * after their name.

Back to the full JSM 2016 program

 
 
Copyright © American Statistical Association